10-Q: ThermoGenesis Holdings Reports Q1 2024 Results: Revenue Up, Losses Narrowed Amidst Financial Challenges

ThermoGenesis Holdings saw a revenue increase in Q1 2024, but continues to face substantial financial challenges and going concern doubts.

Summary

• ThermoGenesis Holdings, Inc. reported its financial results for the quarter ended March 31, 2024.
• Net revenues increased by 6% to $2.737 million compared to $2.572 million in the same period last year, driven by higher AXP disposable sales.
• The company's gross profit increased by 9% to $1.202 million.
• Selling, general, and administrative expenses decreased by 16% to $1.548 million due to cost-cutting initiatives.
• Research and development expenses decreased by 31% to $211,000.
• Interest expense decreased significantly by $2.451 million to $1.452 million due to lower amortization expenses related to convertible notes.
• The net loss attributable to common stockholders was $1.856 million, compared to $5.086 million in the prior year.
• The company's cash and cash equivalents were $1.176 million as of March 31, 2024.
• The company has a working capital deficit of $3.953 million.
• ThermoGenesis acknowledges substantial doubt about its ability to continue as a going concern within one year from the filing date.
• The company is seeking additional funding through debt, equity, or strategic partnerships.
• The company received a notice from Nasdaq regarding non-compliance with minimum stockholders' equity requirements and is developing a plan to regain compliance.
• A related party convertible note was amended, extending the maturity date to December 31, 2024.
• The company is expanding its business to include contract development and manufacturing services (CDMO) for cell and cell-based gene therapies, having completed a new facility in October 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue and gross profit increased, and losses narrowed, the company faces significant financial challenges, including going concern doubts and Nasdaq compliance issues. The expansion into CDMO services is a positive development, but its success is uncertain.

Positives

• Net revenues increased by 6% to $2.737 million, indicating growth in sales.
• Gross profit increased by 9% to $1.202 million, suggesting improved profitability.
• Selling, general, and administrative expenses decreased by 16% to $1.548 million, reflecting successful cost-cutting efforts.
• Research and development expenses decreased by 31% to $211,000, potentially streamlining operations.
• Interest expense decreased significantly by $2.451 million to $1.452 million, easing the financial burden.
• The company completed a new CDMO facility in October 2023, expanding its business into a high-growth area.
• The net loss attributable to common stockholders decreased from $5.086 million to $1.856 million.

Negatives

• The company has a working capital deficit of $3.953 million, indicating short-term financial strain.
• ThermoGenesis acknowledges substantial doubt about its ability to continue as a going concern within one year.
• The company received a Nasdaq notice regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.
• Cash and cash equivalents were $1.176 million as of March 31, 2024, a decrease from $2.000 million at the end of 2023.

Risks

• The company's ability to continue as a going concern is uncertain due to historical losses and the need for additional capital.
• Failure to obtain additional funding through debt, equity, or strategic partnerships could severely impact operations.
• Non-compliance with Nasdaq's minimum stockholders' equity requirements could lead to delisting, reducing liquidity and market access.
• Reliance on a related party for convertible debt financing poses potential conflicts of interest.
• The company's success in the new CDMO business is subject to market acceptance and competition.
• The company depends on a single supplier for AXP disposables, creating supply chain vulnerability.
• The company has material weaknesses in internal control over financial reporting, specifically regarding segregation of duties, which could lead to financial misstatements.

Future Outlook

The company expects to continue incurring operating losses in the near future and will need to raise additional capital to grow its business, fund operating expenses, and make interest payments. The company is seeking additional funding through debt borrowings, sales of debt or equity securities, or strategic partnerships.

Industry Context

The company's expansion into CDMO services for cell and cell-based gene therapies aligns with the growing demand for manufacturing support in the cell therapy industry, where manufacturing bottlenecks and regulatory complexities are significant challenges. The company believes it can leverage its existing cell processing technologies to effectively develop CDMO capabilities.

Comparison to Industry Standards

• It's difficult to directly compare ThermoGenesis's results to industry standards without knowing the specific sub-segments they operate in and the size of their target market.
• However, generally, companies in the cell therapy and bio-banking space are often compared to companies like Cryo-Cell International, Inc. (although Cryo-Cell focuses more on storage and less on device manufacturing) or larger life sciences companies with cell therapy divisions.
• ThermoGenesis's revenue is relatively small compared to established CDMOs like Lonza or Catalent, but these are much larger, diversified companies.
• The key will be to assess ThermoGenesis's growth rate in the CDMO space and its ability to secure contracts and scale its operations effectively.

Related Party Transactions

• The company has a convertible promissory note and revolving credit agreement with Boyalife Group Inc., owned and controlled by the company's CEO and Chairman.
• The company leases laboratory and office space from Z3 Investment LLC, an affiliate of the company's Chairman and CEO, and COO.

Stakeholder Impact

• Shareholders face the risk of delisting from Nasdaq and potential dilution from future equity offerings.
• Employees face uncertainty due to the company's going concern doubts and potential cost-cutting measures.
• Customers may be concerned about the company's long-term viability and ability to fulfill contracts.
• Suppliers may face increased credit risk due to the company's financial challenges.
• Creditors face the risk of non-payment due to the company's liquidity issues.

Next Steps

• The company must submit a plan to Nasdaq to regain compliance with minimum stockholders' equity requirements by July 8, 2024.
• The company will seek additional funding through debt, equity, or strategic partnerships.
• The company will focus on expanding its CDMO business and securing contracts for its new facility.
• The company intends to work to remediate the material weaknesses identified above, which are expected to be the addition of accounting and financial personnel allowing the Company to have sufficient segregation of duties.

Key Dates

Keywords

ThermoGenesis, CDMO, Convertible Note, Revenue, Net Loss, Going Concern, Nasdaq, AXP, BioArchive, Cell Therapy